Estelle S. Harris
No Rating Available
(Learn About Our Rating System)

Estelle S. Harris, MD

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

Pulmonary, Clinic 3
50 N Medical Dr
Salt Lake City , UT 84132
801-581-7806
Get Directions

  • Estelle S. Harris, MD is a Professor of Medicine at the University of Utah Health Science Center. As a Pulmonary and Critical Care physician, her clinical interests include general pulmonary consultation, acute lung injury, non-invasive ventilation, neuromuscular abnormalities and diaphragm muscle dysfunction. Dr. Harris received her MD from the University of Colorado. She received training in Internal Medicine at Boston City Hospital, Boston University, and her Pulmonary and Critical Care training from the University of Michigan.

    Dr. Harris is the Medical Director of the University of Utah medical intensive care unit (ICU) and the Huntsman Cancer Hospital ICU/intermediate care unit. She is also the pulmonary consultant for the neuromuscular clinics at Neurosciences Center and the NeuRx Diaphragm Stimulator Program. She is currently a member of the American Thoracic Society, The American College of Chest Physicians and the Society of Critical Care Medicine.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Critical Care Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)

  • Estelle S. Harris, MD is a Professor of Medicine at the University of Utah Health Science Center. As a Pulmonary and Critical Care physician, her clinical interests include general pulmonary consultation, acute lung injury, non-invasive ventilation, neuromuscular abnormalities and diaphragm muscle dysfunction. Dr. Harris received her MD from the University of Colorado. She received training in Internal Medicine at Boston City Hospital, Boston University, and her Pulmonary and Critical Care training from the University of Michigan.

    Dr. Harris is the Medical Director of the University of Utah medical intensive care unit (ICU) and the Huntsman Cancer Hospital ICU/intermediate care unit. She is also the pulmonary consultant for the neuromuscular clinics at Neurosciences Center and the NeuRx Diaphragm Stimulator Program. She is currently a member of the American Thoracic Society, The American College of Chest Physicians and the Society of Critical Care Medicine.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor (Clinical)
    Academic Divisions Public Health
    Board Certification
    American Board of Internal Medicine (Sub: Critical Care Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)

    Education history

    Undergraduate Biology - Claremont McKenna (Men's) College B.A.
    Professional Medical Medicine - University of Colorado School of Medicine M.D.
    Residency Internal Medicine - Boston City Hospital Resident
    Fellowship Pulmonary/Critical Care - University of Michigan Hospitals Fellow

    Selected Publications

    Journal Article

    1. Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, Mostyka M, Baxter-Stoltzfus A, Borczuk AC, Loda M, Cody MJ, Manne BK, Portier I, Harris ES, Petrey AC, Beswick EJ, Caulin AF, Iovino A, Abegglen LM, Weyrich AS, Rondina MT, Egeblad M, Schiffman JD, Yost C (2020). Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood, 136(10), 1169-1179. (Read full publication)
    2. Middleton EA, Rowley JW, Campbell RA, Grissom CK, Brown SM, Beesley SJ, Schwertz H, Kosaka Y, Manne BK, Krauel K, Tolley ND, Eustes AS, Guo L, Paine R 3rd, Harris ES, Zimmerman GA, Weyrich AS, Rondina M (2019). Sepsis alters the transcriptional and translational landscape of human and murine platelets. Blood, 134(12), 911-923. (Read full publication)
    3. Harris ES, Shigeoka AO, Li W, Adams RH, Prescott SM, McIntyre TM, Zimmerman GA, Lorant D (2001). A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by beta1 and beta2 integrins. Blood, 97(3), 767-76. (Read full publication)
    4. Galt SW, Lindemann S, Medd D, Allen LL, Kraiss LW, Harris ES, Prescott SM, McIntyre TM, Weyrich AS, Zimmerman G (2001). Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circulation research, 89(6), 509-16. (Read full publication)
    5. Harris ES, McIntyre TM, Prescott SM, Zimmerman G (2000). The leukocyte integrins. The Journal of biological chemistry, 275(31), 23409-12. (Read full publication)
    6. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM, National Heart, Lung, and Blood Institute PETAL Clinical Trials Network., Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton-Thompson S, De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, Seethala R, Johnsky L, Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapiro N, Talmor D, O'Mara T, Kirk C, Harrison K, Kurt L, Schermerhorn M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parry B, Lavin-Parsons K, Pulido N, Lilley B, Lodenstein C, Margolin J, Brait K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, Calfee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, Rogers A, Vojnik R, Roque J, Albertson T, Chenoweth J, Adams J, Pearson S, Juarez M, Almasri E, Fayed M, Hughes A, Hillard S, Huebinger R, Wang H, Vidales E, Patel B, Ginde A, Moss M, Baduashvili A, McKeehan J, Finck L, Higgins C, Howell M, Douglas I, Haukoos J, Hiller T, Lyle C, Cupelo A, Caruso E, Camacho C, Gravitz S, Finigan J, Griesmer C, Park P, Hyzy R, Nelson K, McDonough K, Olbrich N, Williams M, Kapoor R, Nash J, Willig M, Ford H, Gardner-Gray J, Ramesh M, Moses M, Ng Gong M, Aboodi M, Asghar A, Amosu O, Torres M, Kaur S, Chen JT, Hope A, Lopez B, Rosales K, Young You J, Mosier J, Hypes C, Natt B, Borg B, Salvagio Campbell E, Hite RD, Hudock K, Cresie A, Alhasan F, Gomez-Arroyo J, Duggal A, Mehkri O, Hastings A, Sahoo D, Abi Fadel F, Gole S, Shaner V, Wimer A, Meli Y, King A, Terndrup T, Exline M, Pannu S, Robart E, Karow S, Hough C, Robinson B, Johnson N, Henning D, Campo M, Gundel S, Seghal S, Katsandres S, Dean S, Khan A, Krol O, Jouzestani M, Huynh P, Weissman A, Yealy D, Scholl D, Adams P, McVerry B, Huang D, Angus D, Schooler J, Moore S, Files C, Miller C, Gibbs K, LaRose M, Flores L, Koehler L, Morse C, Sanders J, Langford C, Nanney K, MdalaGausi M, Yeboah P, Morris P, Sturgill J, Seif S, Cassity E, Dhar S, de Wit M, Mason J, Goodwin A, Hall G, Grady A, Chamberlain A, Brown S, Bledsoe J, Leither L, Peltan I, Starr N, Fergus M, Aston V, Montgomery Q, Smith R, Merrill M, Brown K, Armbruster B, Harris E, Middleton E, Paine R, Johnson S, Barrios M, Eppensteiner J, Limkakeng A, McGowan L, Porter T, Bouffler A, Leahy JC, deBoisblanc B, Lammi M, Happel K, Lauto P, Self W, Casey J, Semler M, Collins S, Harrell F, Lindsell C, Rice T, Stubblefield W, Gray C, Johnson J, Roth M, Hays M, Torr D, Zakaria A, Schoenfeld D, Thompson T, Hayden D, Ringwood N, Oldmixon C, Ulysse C, Morse R, Muzikansky A, Fitzgerald L, Whitaker S, Lagakos A, Brower R, Reineck L, Aggarwal N, Bienstock K, Freemer M, Maclawiw M, Weinmann G, Morrison L, Gillespie M, Kryscio R, Brodie D, Zareba W, Rompalo A, Boeckh M, Parsons P, Christie J, Hall J, Horton N, Zoloth L, Dickert N, Diercks (2020). Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA, 324(21), 2165-2176. (Read full publication)
    7. ACTIV-3/TICO LY-CoV555 Study Group., Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Davey VJ, Goodman A, Higgs ES, Murray DD, Murray TA, Paredes R, Parmar MKB, Phillips AN, Reilly C, Sharma S, Dewar RL, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton J (2021). A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. The New England journal of medicine, 384(10), 905-914. (Read full publication)
    8. Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR Jr, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW, Passive Immunity Trial for Our Nation (PassITON) Investigators (2021). Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Trials, 22(1), 221. (Read full publication)
    9. Brown SM, Peltan ID, Webb B, Kumar N, Starr N, Grissom C, Buckel WR, Srivastava R, Harris ES, Leither LM, Johnson SA, Paine R 3rd, Greene (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. Annals of the American Thoracic Society, 17(8), 1008-1015. (Read full publication)
    10. Brown SM, Peltan I, Kumar N, Leither L, Webb BJ, Starr N, Grissom CK, Buckel WR, Srivastava R, Butler AM, Groat D, Haaland B, Ying J, Harris E, Johnson S, Paine R 3rd, Greene (2020). Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. Annals of the American Thoracic Society, (Read full publication)
    11. Self WH, Wheeler AP, Stewart TG, Schrager H, Mallada J, Thomas CB, Cataldo VD, O'Neal HR Jr, Shapiro NI, Higgins C, Ginde AA, Chauhan L, Johnson NJ, Henning DJ, Jaiswal SJ, Mammen MJ, Harris ES, Pannu SR, Laguio-Vila M, El Atrouni W, de Wit M, Hoda D, Cohn CS, McWilliams C, Shanholtz C, Jones AE, Raval JS, Mucha S, Ipe TS, Qiao X, Schrantz SJ, Shenoy A, Fremont RD, Brady EJ, Carnahan RH, Chappell JD, Crowe JE Jr, Denison MR, Gilchuk P, Stevens LJ, Sutton RE, Thomsen I, Yoder SM, Bistran-Hall AJ, Casey JD, Lindsell CJ, Wang L, Pulley JM, Rhoads JP, Bernard GR, Rice TW, Passive Immunity Trial for Our Nation (PassITON) Investigators (2022). Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized with COVID-19: A Blinded Randomized Placebo-Controlled Trial. Chest, 162(5), 982 - 994. (Read full publication)
    12. Paine R, Chasse R, Halstead ES, Nfonoyim J, Park DJ, Byun T, Patel B, Molina-Pallete G, Harris ES, Garner F, Simms L, Ahuja S, McManus JL, Roychowdhury D (2022). Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm). Military medicine, (Read full publication)
    13. Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L, Peltan ID, Lanspa M, Gilstrap DL, Mourad A, Lane K, Beitler JR, Serra AL, Garcia I, Almasri E, Fayed M, Hubel K, Harris ES, Middleton EA, Barrios MAG, Mathews KS, Goel NN, Acquah S, Mosier J, Hypes C, Salvagio Campbell E, Khan A, Hough CL, Wilson JG, Levitt JE, Duggal A, Dugar S, Goodwin AJ, Terry C, Chen P, Torbati S, Iyer N, Sandkovsky US, Johnson NJ, Robinson BRH, Matthay MA, Aggarwal NR, Douglas IS, Casey JD, Hache-Marliere M, Georges Youssef J, Nkemdirim W, Leshnower B, Awan O, Pannu S, O'Mahony DS, Manian P, Awori Hayanga JW, Wortmann GW, Tomazini BM, Miller RF, Jensen JU, Murray DD, Bickell NA, Zatakia J, Burris S, Higgs ES, Natarajan V, Dewar RL, Schechner A, Kang N, Arenas-Pinto A, Hudson F, Ginde AA, Self WH, Rogers AJ, Oldmixon CF, Morin H, Sanchez A, Weintrob AC, Cavalcanti AB, Davis-Karim A, Engen N, Denning E, Taylor Thompson B, Gelijns AC, Kan V, Davey VJ, Lundgren JD, Babiker AG, Neaton JD, Lane HC, ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Study Grou (2023). Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. The Lancet. Respiratory medicine, 11(9), 791-803. (Read full publication)
    14. Lewis NM, Harker EJ, Grant LB, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Hough CL, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Martinez A, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Goyal A, DeLamielleure LE, DeCuir J, Surie D, Dawood FS, Tenforde MW, Uyeki TM, Garg S, Ellington S, Self WH, Investigating Respiratory Viruses in the Acutely Ill (IVY) Networ (2024). Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study. Clinical infectious diseases, 81(1), 190-197. (Read full publication)
    15. Lewis NM, Harker EJ, Leis A, Zhu Y, Talbot HK, Grijalva CG, Halasa N, Chappell JD, Johnson CA, Rice TW, Casey JD, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, DeCuir J, Surie D, Dawood FS, Ellington S, Self WH, Martin E (2025). Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine, 43(Pt 2), 126492. (Read full publication)
    16. Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Saeed S, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Parikh B, Exline MC, Vaughn IA, Ramesh M, Safdar B, Mosier J, Harris ES, Shapiro NI, Felzer J, Zhu Y, Grijalva CG, Halasa N, Chappell JD, Womack KN, Rhoads JP, Baughman A, Swan SA, Johnson CA, Rice TW, Casey JD, Blair PW, Han JH, Ellington S, Lewis NM, Thornburg N, Paden CR, Atherton LJ, Self WH, Dawood FS, DeCuir (2024). Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Clinical infectious diseases, (Read full publication)
    17. Ware LB, Files DC, Fowler A, Aboodi MS, Aggarwal NR, Brower RG, Chang SY, Douglas IS, Fields S, Foulkes AS, Ginde AA, Harris ES, Hendey GW, Hite RD, Huang W, Lai P, Liu KD, Thompson BT, Matthay MA, National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Networ (2024). Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial. JAMA, 332(5), 390-400. (Read full publication)
    18. Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Barron MA, Reese SE, McEvoy C, Sheffield T, Naleway AL, Zerbo O, Rogerson C, Self WH, Zhu Y, Lauring AS, Martin ET, Peltan ID, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker ME, Mohamed A, Johnson N, Steingrub JS, Khan A, Felzer JR, Duggal A, Wilson JG, Qadir N, Mallow C, Kwon JH, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Chappell JD, Halasa N, Johnson C, Natarajan K, Lewis NM, Ellington S, Reeves EL, DeCuir J, McMorrow M, Paden CR, Payne AB, Dawood FS, Surie D, CDC COVID-19 Vaccine Effectiveness Collaborator (2025). Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ¿18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR. Morbidity and mortality weekly report, 74(6), 73-82. (Read full publication)
    19. Collins SP, Shotwell MS, Strich JR, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock K, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine NM, Tiffany B, Douglas I, Levitt J, Ginde AA, Hager DN, Shapiro N, Duggal A, Khan A, Lanspa M, Chen P, Gentile N, Harris E, Gong M, Sellers S, Goodwin AJ, Tidswell MA, Filbin M, Desai N, Gutiérrez F, Estrada V, Burgos J, Boyles T, Paño-Pardo JR, Hussen N, Rosenberg Y, Troendle J, Bernard GR, Bistran-Hall AJ, Walsh K, Casey JD, DeClercq J, Joly MM, Pulley J, Rice TW, Schildcrout JS, Wang L, Semler MW, Self WH, ACTIV-4 Host Tissue Investigator (2024). Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial. JAMA network open, 7(12), e2448215. (Read full publication)
    20. Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Saeed S, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Parikh B, Exline MC, Vaughn IA, Ramesh M, Safdar B, Mosier J, Harris ES, Shapiro NI, Felzer J, Zhu Y, Grijalva CG, Halasa N, Chappell JD, Womack KN, Rhoads JP, Baughman A, Swan SA, Johnson CA, Rice TW, Casey JD, Blair PW, Han JH, Ellington S, Lewis NM, Thornburg N, Paden CR, Atherton LJ, Self WH, Dawood FS, DeCuir (2024). Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. (Read full publication)
    21. Jensen TO, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER, ACTIV-3/TICO Study Grou (2024). Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study. The Lancet. Microbe, 5(6), e559-e569. (Read full publication)
    22. Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP, ACTIV-1 IM Study Grou (2024). Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. JAMA network open, 7(4), e247615. (Read full publication)
    23. DeCuir J, Payne AB, Self WH, Rowley EAK, Dascomb K, DeSilva MB, Irving SA, Grannis SJ, Ong TC, Klein NP, Weber ZA, Reese SE, Ball SW, Barron MA, Naleway AL, Dixon BE, Essien I, Bride D, Natarajan K, Fireman B, Shah AB, Okwuazi E, Wiegand R, Zhu Y, Lauring AS, Martin ET, Gaglani M, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker M, Mohamed A, Srinivasan V, Steingrub JS, Khan A, Busse LW, Duggal A, Wilson JG, Chang SY, Mallow C, Kwon JH, Exline MC, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Casey JD, Chappell JD, Grijalva CG, Swan SA, Johnson C, Lewis NM, Ellington S, Adams K, Tenforde MW, Paden CR, Dawood FS, Fleming-Dutra KE, Surie D, Link-Gelles R, CDC COVID-19 Vaccine Effectiveness Collaborator (2024). Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ¿18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR. Morbidity and mortality weekly report, 73(8), 180-188. (Read full publication)
    24. Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, Martin ET, House S, Saade EA, Zimmerman RK, Gaglani M, Wernli KJ, Walter EB, Michaels MG, Staat MA, Weinberg GA, Selvarangan R, Boom JA, Klein EJ, Halasa NB, Ginde AA, Gibbs KW, Zhu Y, Self WH, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Weber ZA, Yang DH, Ball SW, Surie D, DeCuir J, Dawood FS, Moline HL, Toepfer AP, Clopper BR, Link-Gelles R, Payne AB, Chung JR, Flannery B, Lewis NM, Olson SM, Adams K, Tenforde MW, Garg S, Grohskopf LA, Reed C, Ellington S, CDC Influenza Vaccine Effectiveness Collaborator (2024). Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. MMWR. Morbidity and mortality weekly report, 73(8), 168-174. (Read full publication)
    25. Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C, ACTIV-3/TICO Study Grou (2024). Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clinical infectious diseases, 78(6), 1490-1503. (Read full publication)
    26. Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER, ACTIV-3/TICO Study Grou (2024). Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. The Journal of infectious diseases, 229(3), 671-679. (Read full publication)
    27. Ma KC, Webber A, Lauring AS, Bendall E, Papalambros LK, Safdar B, Ginde AA, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Busse LW, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Mosier JM, Leis AM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Rice TW, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Zhu Y, Self WH, Dawood FS, Surie (2025). Effectiveness of 2024-2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes - IVY Network, 26 Hospitals, September 1, 2024-April 30, 2025. (Read full publication)
    28. Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, Ginde AA, Simon SJ, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Felzer JR, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Papalambros L, Mosier JM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Rutkowski RE, Ma KC, Dawood FS, Investigating Respiratory Viruses in the Acutely Ill (IVY) Networ (2025). RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA, (Read full publication)
    29. Ma KC, Surie D, Zhu Y, Grijalva CG, Blair PW, Safdar B, Ginde AA, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Hough CL, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Busse LW, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Lauring AS, Martin ET, Leis AM, Mosier JM, Harris ES, Baughman A, Johnson C, Casey JD, Halasa N, Chappell JD, Lewis N, Ellington S, Self WH, Dawood F (2025). Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults with Respiratory Syncytial Virus. Clinical infectious diseases, (Read full publication)
    30. Aoki JA, Denorme F, Cody MJ, Perry DP, Rustad JL, Brown SM, Goldstein SA, Middleton EA, Yost CC, Harris ES, NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Network Investigator (2025). Plasma surrogate markers of neutrophil extracellular traps correlate with disease severity in patients with moderate to severe acute respiratory distress syndrome. Journal of inflammation (London, England), 22(1), 22. (Read full publication)
    31. Lewis NM, Harker EJ, Cleary S, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Halasa NB, Lauring AS, Martin ET, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Duggal A, Felzer JR, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Ferguson SAN, Mosier J, Qadir N, Chang SY, Ginde AA, Zepeski A, Mallow C, Harris ES, Johnson NJ, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Surie D, Dawood FS, Ellington S, Self W (2025). Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024. The Journal of infectious diseases, 232(4), e626-e636. (Read full publication)
    32. Surie D, Yuengling KA, Safdar B, Ginde AA, Peltan ID, Brown SM, Gaglani M, Ghamande S, Gottlieb RL, Columbus C, Mohr NM, Gibbs KW, Hager DN, O'Rourke M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Busse LW, Felzer J, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Lauring AS, Martin ET, Mosier JM, Harris ES, Baughman A, Swan SA, Johnson CA, Blair PW, Lewis NM, Ellington S, Rutkowski RE, Zhu Y, Self WH, Dawood FS, Investigating Respiratory Viruses in the Acutely Ill (IVY) Networ (2025). Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination. JAMA network open, 8(4), e252841. (Read full publication)
    33. Lauring AS, Edson C, Surie D, Dawood FS, Self WH, Lucero-Obusan C, Holodniy M, IVY Networ (2025). Genomic Characterization of RSV in the US by Vaccination Status. JAMA, 333(17), 1540-1543. (Read full publication)